Literature DB >> 17329914

Hyperglycemia promotes microinflammation as evaluated by C-reactive protein in the very elderly.

Masayo Fukuhara1, Kiyoshi Matsumura, Masanori Wakisaka, Yutaka Takata, Kazuo Sonoki, Kiyoshi Fujisawa, Toshihiro Ansai, Sumio Akifusa, Koji Fujii, Mitsuo Iida, Tadamichi Takehara.   

Abstract

OBJECTIVE: C-reactive protein (CRP) is not only an acute phase reactant but also a sensitive marker of subclinical inflammation associated with atherosclerosis. The aim of the present study was to determine whether glycemic control or blood pressure influences the vascular microinflammation as evaluated by CRP levels in the very elderly.
METHODS: The study group consisted of 195 residents aged 85 years. The subjects were divided into three groups according to their CRP levels; a low (<1 mg/L), an average (1 to 3 mg/L), and a high (3 to 10 mg/L) CRP group. Hemoglobin A(1c) (HbA(1c)) levels were used as an index of glycemic control.
RESULTS: The HbA(1c) level showed a significant positive correlation with the CRP level (r=0.289, p<0.0001). In contrast, systolic and diastolic blood pressures failed to correlate with the CRP level. The HbA(1c) was significantly greater in the high CRP group compared to the average and the low CRP groups (6.01+/-0.29%, 5.57+/-0.09% and 5.42+/-0.05%, respectively). Furthermore, the HbA(1c) adjusted by sex, body mass index, systolic blood pressure, serum triglyceride and current smoking status was significantly higher in the high CRP group than in the average and the low CRP groups. Multiple regression analysis also revealed that the HbA(1c) level was significantly and independently associated with the CRP level.
CONCLUSIONS: These results suggest that tight good glycemic control, even in very elderly subjects, may be able to reduce the systemic inflammation that contributes to leads to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329914     DOI: 10.2169/internalmedicine.46.1868

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

1.  High sensitivity C-reactive protein associated with different health predictors in middle-aged and oldest old Chinese.

Authors:  Yi Zhai; Xiao Ming Shi; Simon Michael Fitzgerald; Han Zhu Qian; Virginia B Kraus; Melanie Sereny; Perry Hu; Zhao Xue Yin; Jian Wei Xu; Yi Zeng
Journal:  Biomed Environ Sci       Date:  2012-06       Impact factor: 3.118

2.  Effect of sesamol on diabetes-associated cognitive decline in rats.

Authors:  Anurag Kuhad; Kanwaljit Chopra
Journal:  Exp Brain Res       Date:  2007-10-23       Impact factor: 1.972

3.  Longitudinal association of C-reactive protein and Haemoglobin A1c over 13 years: the European Prospective Investigation into Cancer--Norfolk study.

Authors:  Sara Ahmadi-Abhari; Stephen Kaptoge; Robert N Luben; Nicholas J Wareham; Kay-Tee Khaw
Journal:  Cardiovasc Diabetol       Date:  2015-05-22       Impact factor: 9.951

Review 4.  Diabetes cognitive impairments and the effect of traditional chinese herbs.

Authors:  Xiaohan Xu; Leilei Guo; Guoqing Tian
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-09       Impact factor: 2.629

5.  Glycated hemoglobin level is an independent predictor of major adverse cardiac events after nonfatal acute myocardial infarction in nondiabetic patients: A retrospective observational study.

Authors:  Chin-Lan Chen; David H-T Yen; Chin-Sheng Lin; Shih-Hung Tsai; Sy-Jou Chen; Wayne H-H Sheu; Chin-Wang Hsu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

6.  High HbA1c is associated with decreased 6-month survival and poor outcomes after out-of-hospital cardiac arrest: a retrospective cohort study.

Authors:  Junhaeng Lee; Joo Suk Oh; Jong Ho Zhu; Sungyoup Hong; Sang Hyun Park; Ji Hoon Kim; Hyungsoo Kim; Mingu Seo; Kiwook Kim; Doo Hyo Lee; Hyun Ho Jung; Jungtaek Park; Young Min Oh; Semin Choi; Kyoung Ho Choi
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2020-09-03       Impact factor: 2.953

7.  Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Authors:  Steven E Kahn; Steven M Haffner; Giancarlo Viberti; William H Herman; John M Lachin; Barbara G Kravitz; Dahong Yu; Gitanjali Paul; Rury R Holman; Bernard Zinman
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.